Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Postbariatric Hypoglycemia
Interventions: exendin 9-39, Placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Contrast-Induced Acute Kidney Injury
Interventions: CRMD-001-Deferiprone, Placebo; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more

Conditions: Peripheral Artery Disease
Interventions: Beetroot juice, Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • Charlottesville, Virginia

Conditions: Parkinson Disease
Interventions: VENT-02, Placebo; Drug
Lead sponsor: Ventus Therapeutics U.S., Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 23
States / cities: Fountain Valley, California • San Jose, California • West Hills, California + 19 more

Conditions: Vasomotor Symptoms, Hot Flashes
Interventions: RAD1901, Placebo; Drug · Other
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy Volunteers
Interventions: ASP1128, Placebo; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: PF-06414300, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: AV608; Drug
Lead sponsor: Avera Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Generalized Myasthenia Gravis
Interventions: Ravulizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more

Conditions: Anxiety, Stage IV Melanoma
Interventions: psilocybin; Drug
Lead sponsor: Multidisciplinary Association for Psychedelic Studies; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Opioid Dependence, Pain
Interventions: Minocycline, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo matching Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 12
States / cities: Chula Vista, California • San Diego, California • Torrance, California + 9 more

Conditions: Cluster Headache - Episodic and Chronic
Interventions: SOM230, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Culver City, California • Philadelphia, Pennsylvania

Conditions: Lung Cancer
Interventions: Pembrolizumab, Epacadostat, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Anaheim, California • Whittier, California • Fort Myers, Florida + 12 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Epilepsy
Interventions: perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Moderate to Severe Glabellar Lines
Interventions: Corabotase, Placebo; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more

Conditions: Cervical Dystonia
Interventions: Valbenazine, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sleep Disturbance, Stress, Feeling Anxious
Interventions: Active Gut Feeling Product 1, Active Gut Feeling Product 2, Placebo Gut Feeling Control Product; Other
Lead sponsor: Holobiome, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions: Study Drug Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Days to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Healthy
Interventions: Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Cataract, Inflammation, Surgery
Interventions: Mapracorat, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Type 2 Diabetes
Interventions: Placebo Attention Control, Supervised Exercise Training; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

BEETroot Juice to Reverse Functional Impairment in PAD

A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

The Effects of Minocycline in Opioid-maintained Patients

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia

GUT-FEELINGS: Using Citizen Science for Large-Scale Prebiotic Clinical Trials for Mental Wellness in Adults

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Trial of Reducing Inpatient Antibiotic Durations in Children

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Barriers to Physical Activity in People With Type 2 Diabetes